ReviewCurrent heart failure reports2026
TIM-3 in Cardiovascular Disease.
Review in Current heart failure reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purpose of reviewWe summarise the current knowledge of T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) across innate and adaptive immune cells and compile emerging evidence in cardiovascular disease (CVD). RECENT
findingsImmune checkpoints have come to light as potent regulators of immune responses in tumour biology, autoimmune disease and, more recently, in CVD. TIM-3 is a complex immune checkpoint expressed on both immune and non-immune cells. It has four known ligands, two of which are only available for binding upon cell damage or death, and binding can be either stimulatory or inhibitory. It functions as a context-dependent modulator of immune reactions in atherosclerosis, myocardial infarction and myocarditis. TIM-3 may exert functions in the cardiovascular system, but more mechanistic research is required to investigate whether interference with TIM-3 signalling can be used to improve cardiovascular health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.